# A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

> **NCT07218003** · PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Rondo Therapeutics** · enrollment: 149 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Cervical Cancer
- Head and Neck Squamous Cell Cancer
- Triple Negative Breast Cancer (TNBC)
- Urothelial Carcinoma Bladder
- Gastroesophageal Junction (GEJ) Adenocarcinoma
- Esophageal Squamous Cell Cancer
- Gastric Cancer
- Cancer
- Solid Tumors (Phase 1)

## Interventions

- **DRUG:** RNDO-564
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07218003
- **Lead sponsor:** Rondo Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-11-17
- **Primary completion:** 2029-02-28
- **Final completion:** 2029-03-31
- **Target enrollment:** 149 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07218003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07218003, "A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07218003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*